According to a new report from Intel Market Research, the global Brigatinib Tablet market was valued at USD 229 million in 2024 and is projected to reach USD 370 million by 2034, growing at a CAGR of 7.3% during the forecast period (2025–2034). This growth trajectory reflects the increasing global prevalence of ALK-positive non-small cell lung cancer (NSCLC) and significant advancements in targeted cancer therapies.
What is Brigatinib Tablet?
Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to target anaplastic lymphoma kinase (ALK) and other oncogenic drivers in NSCLC. Approved as ALUNBRIG® by Takeda Pharmaceuticals, it represents a critical second-line treatment option for patients who develop resistance to first-generation ALK inhibitors like crizotinib. The drug's unique dual mechanism - inhibiting both ALK and EGFR mutations - provides broader efficacy against treatment-resistant cancer cells while demonstrating superior brain penetration to combat metastatic lesions.
This comprehensive report delivers a 360-degree view of the global Brigatinib Tablet market, analyzing everything from macroeconomic factors to granular competitive dynamics. We examine market size trajectories, regulatory landscapes across key regions, pipeline developments, and strategic initiatives by industry leaders. The analysis empowers stakeholders to identify high-growth segments, assess competitive threats, and make data-driven decisions in this rapidly evolving therapeutic area.
For pharmaceutical executives, healthcare investors, and clinical researchers, this report serves as an essential roadmap to navigate the ALK inhibitor market's complexities. It combines rigorous quantitative analysis with qualitative insights on treatment adoption barriers, reimbursement challenges, and emerging technological disruptions in precision oncology.
? Download Sample Report: Brigatinib Tablet Market - View in Detailed Research Report
Key Market Drivers
1. Rising ALK+ NSCLC Prevalence and Diagnostic Advancements
The increasing incidence of ALK-positive NSCLC - accounting for approximately 5% of all lung cancer cases - creates sustained demand for targeted therapies. Improved molecular diagnostics now enable routine ALK rearrangement testing, with next-generation sequencing (NGS) panels achieving 95% detection accuracy in clinical settings. Brigatinib's superior efficacy in crizotinib-resistant cases positions it as a preferred second-line option, especially given its 78% intracranial response rate against brain metastases.
2. Expanding Treatment Guidelines and Clinical Validation
Recent updates to NCCN and ESMO treatment guidelines now recommend Brigatinib as both second-line therapy and, increasingly, as first-line treatment for ALK+ NSCLC. Clinical trial data demonstrates remarkable 24-month progression-free survival rates of 48.7% versus 26.4% for comparator drugs. Such robust clinical evidence continues to drive formulary inclusion across major healthcare systems, with over 65% of U.S. oncology centers now including Brigatinib in standard treatment protocols.
Market Challenges
- Premium Pricing and Access Barriers - With annual treatment costs exceeding $150,000 in developed markets, affordability remains a significant hurdle. Even with insurance coverage, 34% of U.S. patients face prohibitive co-pays, while many emerging markets lack reimbursement mechanisms entirely.
- Emerging Therapeutic Competition - Third-generation ALK inhibitors like lorlatinib demonstrate improved CNS activity and resistance profiles, threatening Brigatinib's market position. Pipeline drugs utilizing novel mechanisms (PROTAC degraders, antibody-drug conjugates) may further disrupt the treatment landscape.
- Complex Treatment Sequencing - Optimal sequencing of ALK inhibitors remains controversial, with some clinicians favoring Brigatinib as first-line therapy. This creates prescriber education challenges and necessitates robust biomarker testing infrastructure.
Emerging Opportunities
The global oncology market presents multiple growth levers for Brigatinib manufacturers:
- Combination Therapy Expansion - Over 40 ongoing clinical trials are evaluating Brigatinib with PD-1/PD-L1 inhibitors, VEGF blockers, and novel agents. Early data shows synergy with immunotherapy in certain patient subsets.
- Emerging Market Penetration - Countries like China and Brazil show 12-15% annual growth in targeted therapy adoption, supported by improving diagnostic capabilities and expanding private healthcare coverage.
- Orphan Drug Designations - Additional indications for rare ALK-positive cancers (inflammatory myofibroblastic tumors, anaplastic large cell lymphoma) could unlock new patient populations and extend market exclusivity.
? Download Sample PDF: Brigatinib Tablet Market - View in Detailed Research Report
Regional Market Insights
- North America: Commands 58% market share due to favorable reimbursement (Medicare Part D coverage), high diagnostic rates, and early adoption of novel therapies. FDA's 2021 approval for first-line use significantly expanded the addressable patient population.
- Europe: Shows heterogeneous adoption due to varying reimbursement policies. Germany and France lead utilization, while cost-effectiveness concerns slow uptake in Southern and Eastern Europe. EMA's approval for brain metastasis indication (2022) drove recent growth.
- Asia-Pacific: The fastest-growing region (12.7% CAGR) as improving healthcare infrastructure enables broader ALK testing. Japan's NHI reimbursement and China's local manufacturing partnerships create high-growth submarkets.
- Latin America/Middle East: Niche opportunities exist in Brazil, Mexico, and GCC countries through specialist cancer centers, though access remains largely limited to private pay patients.
Market Segmentation
By Dosage Strength
- 30mg Tablets (lead-in dose)
- 50mg Tablets
- 180mg Tablets (maintenance therapy)
By Treatment Line
- First-line Therapy
- Second-line Therapy
- Salvage Therapy
By Distribution Channel
- Hospital Pharmacies (58% share)
- Specialty Cancer Centers
- Mail-order Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
? Get Full Report Here: Brigatinib Tablet Market - View Detailed Research Report
Competitive Landscape
Takeda Pharmaceutical dominates the Brigatinib market through strategic control of the ALUNBRIG® brand, supported by an extensive oncology commercialization infrastructure. However, the competitive environment is intensifying:
- Pfizer and Novartis are advancing next-generation ALK inhibitors with improved CNS penetration
- Biotech firms like Turning Point Therapeutics are developing novel resistance-overcoming compounds
- Generic manufacturers have begun patent challenge proceedings, though significant market entry isn't expected before 2026
The report provides detailed competitive intelligence on 15+ companies, analyzing their:
- Pipeline developments and clinical trial strategies
- Pricing and market access approaches
- Geographic expansion plans
- Strategic partnerships with diagnostic companies
Report Deliverables
- Market size projections through 2034 with scenario analysis
- Clinical trial landscape and regulatory approval timelines
- Sales force effectiveness benchmarks
- Patient flow models and treatable population analysis
- Reimbursement policy comparisons across 25 countries
? Get Full Report Here: Brigatinib Tablet Market - View Detailed Research Report
? Download Sample Report: Brigatinib Tablet Market - View in Detailed Research Report
About Intel Market Research
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
- Real-time competitive benchmarking
- Global clinical trial pipeline monitoring
- Country-specific regulatory and pricing analysis
- Over 500+ healthcare reports annually
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
? Website: https://www.intelmarketresearch.com
? Asia-Pacific: +91 9169164321
? LinkedIn: Follow Us
Comments